Jeremy Rubinstein

18PUBLICATIONS

83CO-AUTHORS

AutoimmunityCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursGene and molecular therapyNeonatology

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (18)

Sort by Publication Date:

|May 15, 2026

Emapalumab for Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome Following CD19-Directed CAR-T in Two Patients With B-ALL: Clinical and Biomarker Correlates.

|Sep 24, 2025

Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction.

Jeremy D Rubinstein, Giang Pham, Anusha Sridharan

|Apr 07, 2025

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia.

Sara K Silbert, Alexander W Rankin, Chloe N Hoang

|Mar 22, 2025

Posttransplant EBV-Positive Smooth Muscle Tumors in Children, Adolescents, and Young Adults: A Multi-Institution Experience.

Meghan Haney, Kaitlin J Devine, Ana C Xavier

|Jul 31, 2024

Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients.

Francis R LeBlanc, Erin H Breese, Karen C Burns

|Feb 23, 2023

Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel.

Thomas J Galletta, Jeremy D Rubinstein, Christa Krupski

Pageof 3

Frequent Collaborators

Christopher E Dandoy

Lauren Pommert

Michael S Grimley

Joseph Pressey

Stella M Davies

Thomas J Galletta

YunZu Michele Wang

James B Ford

Jose A Cancelas

Francis R LeBlanc

Frequent Collaborators

Christopher E Dandoy

Lauren Pommert

Michael S Grimley

Joseph Pressey